{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T22:48:27Z","timestamp":1793486907447,"version":"4.5.0"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"38","license":[{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,18]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Benign prostatic hyperplasia (BPH) is a leading cause of lower urinary tract symptoms in older men and imposes a growing health burden on aging populations. However, the association between serum uric acid levels and BPH remains inconclusive, and evidence from Chinese populations is scarce. This study investigates the prospective association between baseline serum uric acid (UA) levels and benign prostatic hyperplasia (BPH) among Chinese men aged 45 years or older, with particular attention to potential nonlinear and subgroup-specific associations. Baseline and follow-up data were obtained from the 2011 and 2015 waves of the China Health and Retirement Longitudinal Study, which used a multistage, stratified probability sampling design. Multivariable logistic regression was conducted to evaluate the association between baseline serum UA levels and BPH using three progressively adjusted models that included 11 covariates: age, education, residence, marital status, smoking status, alcohol consumption, body mass index, hypertension, history of cardiovascular disease, diabetes, and dyslipidemia. Restricted cubic spline regression was applied to examine potential nonlinear and dose-response associations. All analyses were performed using R version 4.3.2. Of the 4755 participants, 250 (5.26%) had BPH at follow-up. After adjustment for covariates, participants in the highest UA quartile (Q4) had higher odds of BPH (odds ratio [OR], 1.025; 95% confidence interval [CI], 1.006\u20131.045). Restricted cubic spline analysis indicated a U-shaped nonlinear association between serum UA levels and BPH (P for nonlinearity\u2005=\u20050.029). Serum UA levels above 5.92\u2009mg\/dL were associated with higher odds of BPH, while each interquartile range increase in UA corresponded to a 19.8% increase in the odds of BPH (OR, 1.198; 95% CI, 1.024\u20131.402). Receiver operating characteristic analysis yielded an area under the curve of 0.779 and identified 5.26\u2009mg\/dL as the optimal cutoff value. Subgroup analyses further showed a significant interaction between serum UA levels and residence. Baseline serum UA levels were nonlinearly associated with BPH at follow-up among Chinese men aged 45 years or older. However, the observational design precludes conclusions regarding causality or clinical utility. These findings should therefore be considered hypothesis-generating and require confirmation in studies using clinically validated BPH outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000050770","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T17:01:00Z","timestamp":1789750860000},"page":"e50770","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Association between serum uric acid and benign prostatic hyperplasia among Chinese men aged 45 years or older"],"prefix":"10.1097","volume":"105","author":[{"given":"Jiangtao","family":"Li","sequence":"first","affiliation":[{"name":"The First Affiliated Hospital, Department of Hepatopancreatobiliary Surgery, Hengyang Medical School, University of South China, Hengyang, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9511-1998","authenticated-orcid":false,"given":"Peng","family":"Cao","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital, Department of Hepatopancreatobiliary Surgery, Hengyang Medical School, University of South China, Hengyang, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6388-2851","authenticated-orcid":false,"given":"Yanfang","family":"Chen","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital, Department of Neurology, Hengyang Medical School, University of South China, Hengyang, Hunan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260922","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/bju.15229","article-title":"Benign prostatic hyperplasia - what do we know?","volume":"127","author":"Devlin","year":"2021","journal-title":"BJU Int"},{"key":"R2-20260922","first-page":"64","article-title":"Epidemiological trends of urinary tract infections, urolithiasis and benign prostatic hyperplasia in 203 countries and territories from 1990 to 2019.","volume":"8","author":"Zhu","year":"2021","journal-title":"Mil Med Res"},{"key":"R3-20260922","first-page":"613","article-title":"Benign prostatic hyperplasia: rapid evidence review.","volume":"107","author":"Arnold","year":"2023","journal-title":"Am Fam Physician"},{"key":"R4-20260922","doi-asserted-by":"crossref","first-page":"123192","DOI":"10.1016\/j.lfs.2024.123192","article-title":"Association between metabolic syndrome and benign prostatic hyperplasia: the underlying molecular connection.","volume":"358","author":"Fu","year":"2024","journal-title":"Life Sci"},{"key":"R5-20260922","doi-asserted-by":"crossref","first-page":"2478875","DOI":"10.1080\/13685538.2025.2478875","article-title":"National prevalence and incidence of benign prostatic hyperplasia\/lower urinary tract symptoms and validated risk factors pattern.","volume":"28","author":"Lin","year":"2025","journal-title":"Aging Male"},{"key":"R6-20260922","doi-asserted-by":"crossref","first-page":"glad187","DOI":"10.1093\/gerona\/glad187","article-title":"Causal associations between lifestyle habits and risk of benign prostatic hyperplasia: a two-sample Mendelian Randomization Study.","volume":"79","author":"Jia","year":"2024","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"R7-20260922","doi-asserted-by":"crossref","first-page":"15579883261436335","DOI":"10.1177\/15579883261436335","article-title":"The association between metabolic syndrome and benign prostatic hyperplasia: a systematic review and meta-analysis.","volume":"20","author":"Gao","year":"2026","journal-title":"Am J Mens Health"},{"key":"R8-20260922","doi-asserted-by":"crossref","first-page":"20420188211066210","DOI":"10.1177\/20420188211066210","article-title":"Metabolic syndrome is associated with prostate enlargement: a systematic review, meta-analysis, and meta-regression on patients with lower urinary tract symptom factors.","volume":"12","author":"Omran","year":"2021","journal-title":"Ther Adv Endocrinol Metab"},{"key":"R9-20260922","doi-asserted-by":"crossref","first-page":"2498105","DOI":"10.1080\/13510002.2025.2498105","article-title":"Is uric acid a true antioxidant? Identification of uric acid oxidation products and their biological effects.","volume":"30","author":"Pinz","year":"2025","journal-title":"Redox Rep"},{"key":"R10-20260922","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41392-024-01916-y","article-title":"Hyperuricemia and its related diseases: mechanisms and advances in therapy.","volume":"9","author":"Du","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"R11-20260922","doi-asserted-by":"crossref","first-page":"12394","DOI":"10.3390\/ijms222212394","article-title":"Uric acid in inflammation and the pathogenesis of atherosclerosis.","volume":"22","author":"Kimura","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R12-20260922","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ejim.2022.04.022","article-title":"Uric acid in metabolic syndrome: does uric acid have a definitive role?","volume":"103","author":"Copur","year":"2022","journal-title":"Eur J Intern Med"},{"key":"R13-20260922","doi-asserted-by":"crossref","first-page":"102271","DOI":"10.1016\/j.redox.2022.102271","article-title":"U-shaped association of uric acid to overall-cause mortality and its impact on clinical management of hyperuricemia.","volume":"51","author":"Crawley","year":"2022","journal-title":"Redox Biol"},{"key":"R14-20260922","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1002\/acr.24476","article-title":"Hypouricemia and mortality risk in the US general population.","volume":"73","author":"D\u2019Silva","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R15-20260922","doi-asserted-by":"crossref","first-page":"18412","DOI":"10.1038\/s41598-022-22025-2","article-title":"Association between metabolic syndrome and uric acid: a systematic review and meta-analysis.","volume":"12","author":"Raya-Cano","year":"2022","journal-title":"Sci Rep"},{"key":"R16-20260922","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/bs.acc.2022.06.002","article-title":"New markers in metabolic syndrome.","volume":"110","author":"Son","year":"2022","journal-title":"Adv Clin Chem"},{"key":"R17-20260922","doi-asserted-by":"crossref","first-page":"111932","DOI":"10.1016\/j.intimp.2024.111932","article-title":"Signaling pathways in uric acid homeostasis and gout: from pathogenesis to therapeutic interventions.","volume":"132","author":"Yang","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"R18-20260922","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3390\/diagnostics14010055","article-title":"Increased risk of benign prostate hyperplasia (BPH) in patients with gout: a longitudinal follow-up study using a National Health Screening Cohort.","volume":"14","author":"Bang","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"R19-20260922","doi-asserted-by":"crossref","first-page":"e14200","DOI":"10.1111\/and.14200","article-title":"Is there relationship between serum uric acid levels and lower urinary tract symptoms, prostate volume, and PSA in men without cancer? A prospective population-based study.","volume":"53","author":"Siroosbakht","year":"2021","journal-title":"Andrologia"},{"key":"R20-20260922","doi-asserted-by":"crossref","first-page":"2275775","DOI":"10.1080\/13685538.2023.2275775","article-title":"Association of serum uric acid levels with benign prostatic hyperplasia in US men: results from NHANES 2005-2008.","volume":"26","author":"Zhou","year":"2023","journal-title":"Aging Male"},{"key":"R21-20260922","doi-asserted-by":"crossref","first-page":"649","DOI":"10.3390\/metabo12070649","article-title":"Higher levels of serum uric acid have a significant association with lower incidence of lower urinary tract symptoms in healthy Korean men.","volume":"12","author":"Hwang","year":"2022","journal-title":"Metabolites"},{"key":"R22-20260922","doi-asserted-by":"crossref","first-page":"101717","DOI":"10.1016\/j.berh.2021.101717","article-title":"Urate transport in health and disease.","volume":"35","author":"Halperin Kuhns","year":"2021","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"R23-20260922","doi-asserted-by":"crossref","first-page":"108615","DOI":"10.1016\/j.pharmthera.2024.108615","article-title":"Uric acid in health and disease: from physiological functions to pathogenic mechanisms.","volume":"256","author":"Wen","year":"2024","journal-title":"Pharmacol Ther"},{"key":"R24-20260922","doi-asserted-by":"crossref","first-page":"e1005","DOI":"10.1016\/S2468-2667(22)00203-1","article-title":"Nowcasting and forecasting the care needs of the older population in China: analysis of data from the China Health and Retirement Longitudinal Study (CHARLS).","volume":"7","author":"Gong","year":"2022","journal-title":"Lancet Public Health"},{"key":"R25-20260922","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1186\/s12877-023-04374-3","article-title":"Association between elevated serum uric acid levels and high estimated glomerular filtration rate with reduced risk of low muscle strength in older people: a retrospective cohort study.","volume":"23","author":"Huang","year":"2023","journal-title":"BMC Geriatr"},{"key":"R26-20260922","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/bju.15286","article-title":"The rising worldwide impact of benign prostatic hyperplasia.","volume":"127","author":"Launer","year":"2021","journal-title":"BJU Int"},{"key":"R27-20260922","first-page":"205","article-title":"The etiology and pathogenesis of benign prostatic hyperplasia: the roles of sex hormones and anatomy.","volume":"16","author":"Xu","year":"2024","journal-title":"Res Rep Urol"},{"key":"R28-20260922","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1111\/iju.15518","article-title":"Chronic inflammation in benign prostatic hyperplasia: pathophysiology and treatment options.","volume":"31","author":"Inamura","year":"2024","journal-title":"Int J Urol"},{"key":"R29-20260922","doi-asserted-by":"crossref","first-page":"e20250343","DOI":"10.1590\/1806-9282.20250343","article-title":"Risk factors for benign prostatic hyperplasia: a comprehensive review.","volume":"71","author":"Siqueira","year":"2025","journal-title":"Rev Assoc Med Bras (1992)"},{"key":"R30-20260922","doi-asserted-by":"crossref","first-page":"e092844","DOI":"10.1136\/bmjopen-2024-092844","article-title":"Cross-sectional study on the association between serum uric acid levels and the risk of benign prostatic hyperplasia.","volume":"15","author":"Hua","year":"2025","journal-title":"BMJ Open"},{"key":"R31-20260922","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1002\/pros.70026","article-title":"Probenecid and eugenol mitigate testosterone induced benign prostatic hyperplasia by targeting uric acid-induced inflammation and pro-survival pathways.","volume":"85","author":"Abdali","year":"2025","journal-title":"Prostate"},{"key":"R32-20260922","doi-asserted-by":"crossref","first-page":"272","DOI":"10.21037\/tau-20-1114","article-title":"Exploration of the association between serum uric acid and testosterone in adult males: NHANES 2011-2016.","volume":"10","author":"Han","year":"2021","journal-title":"Transl Androl Urol"},{"key":"R33-20260922","doi-asserted-by":"crossref","first-page":"17323","DOI":"10.1038\/s41598-021-96959-4","article-title":"Establishment of sex difference in circulating uric acid is associated with higher testosterone and lower sex hormone-binding globulin in adolescent boys.","volume":"11","author":"Wang","year":"2021","journal-title":"Sci Rep"},{"key":"R34-20260922","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/iju.15446","article-title":"Intrinsic and extrinsic factors causing hyperplasia of the prostate.","volume":"31","author":"Kyoda","year":"2024","journal-title":"Int J Urol"},{"key":"R35-20260922","doi-asserted-by":"crossref","first-page":"e446","DOI":"10.1002\/edm2.446","article-title":"Serum uric acid to high-density lipoprotein ratio as a novel indicator of inflammation is correlated with the presence and severity of metabolic syndrome: a large-scale study.","volume":"6","author":"Kolahi Ahari","year":"2023","journal-title":"Endocrinol Diabetes Metab"},{"key":"R36-20260922","doi-asserted-by":"crossref","first-page":"842008","DOI":"10.3389\/fimmu.2022.842008","article-title":"Immune cell proinflammatory microenvironment and androgen-related metabolic regulation during benign prostatic hyperplasia in aging.","volume":"13","author":"Cao","year":"2022","journal-title":"Front Immunol"},{"key":"R37-20260922","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.3390\/cancers15123110","article-title":"The molecular basis and clinical consequences of chronic inflammation in prostatic diseases: prostatitis, benign prostatic hyperplasia, and prostate cancer.","volume":"15","author":"Oseni","year":"2023","journal-title":"Cancers (Basel)"},{"key":"R38-20260922","doi-asserted-by":"crossref","first-page":"103511","DOI":"10.1016\/j.autrev.2023.103511","article-title":"Benign prostatic hyperplasia - a novel autoimmune disease with a potential therapy consequence?","volume":"23","author":"Liedtke","year":"2024","journal-title":"Autoimmun Rev"},{"key":"R39-20260922","doi-asserted-by":"crossref","first-page":"115122","DOI":"10.1016\/j.taap.2020.115122","article-title":"The modulatory effects of cinnamaldehyde on uric acid level and IL-6\/JAK1\/STAT3 signaling as a promising therapeutic strategy against benign prostatic hyperplasia.","volume":"402","author":"Afify","year":"2020","journal-title":"Toxicol Appl Pharmacol"},{"key":"R40-20260922","doi-asserted-by":"crossref","first-page":"12","DOI":"10.5213\/inj.2040234.117","article-title":"Correlation between testosterone replacement treatment and lower urinary tract symptoms.","volume":"25","author":"Lee","year":"2021","journal-title":"Int Neurourol J"},{"key":"R41-20260922","doi-asserted-by":"crossref","first-page":"6785","DOI":"10.3390\/ijms27156785","article-title":"Elevated estradiol and DHT levels in the prostatic stroma as key drivers of benign prostatic hyperplasia pathogenesis.","volume":"27","author":"Pej\u010di\u0107","year":"2026","journal-title":"Int J Mol Sci"},{"key":"R42-20260922","doi-asserted-by":"crossref","first-page":"469580261422684","DOI":"10.1177\/00469580261422684","article-title":"Urban-rural differences in self-reported physician-diagnosed BPH and associated factors among older men: a cross-sectional analysis of a national survey.","volume":"63","author":"Meng","year":"2026","journal-title":"Inquiry"},{"key":"R43-20260922","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12937-026-01310-0","article-title":"Food ultra-processing, plant-origin foods, and risk of benign prostatic hyperplasia: evidence from the UK Biobank cohort.","volume":"25","author":"Yang","year":"2026","journal-title":"Nutr J"},{"key":"R44-20260922","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11934-026-01346-z","article-title":"Exercise and physical activity as modifiable risk factors for benign prostatic hyperplasia: an update.","volume":"27","author":"Branco","year":"2026","journal-title":"Curr Urol Rep"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050770","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T18:03:59Z","timestamp":1790100239000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050770"}},"subtitle":["A prospective cohort study"],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":44,"journal-issue":{"issue":"38","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000050770","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,18]]},"assertion":[{"value":"2025-12-08","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-02","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}